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E pilepsy is a severe neurological disorder charac-terized by spontaneous and recurrent seizures,  
affecting about 1% of the general population of all ages 
and races in the world.  However,  the mechanisms of 
epileptogenesis remain unknown.  Epilepsy is often 
refractory to pharmacological treatment [1].  For exam-
ple,  about one third of patients are resistant to anti- 
epileptic drugs (AEDs) [2 , 3].  Additionally,  current 
AEDs relieve symptoms rather than interfere with the 
causal mechanisms of the disease,  and therefore do not 
cure the disorder.  Thus,  the development of a novel 
anti-epileptic therapeutic is crucial.  Usually,  most 
patients do not realize that they have epilepsy until they 
start experiencing seizures.  Clinical trial designs for 
novel therapeutics against epileptogenesis are hampered 
by the lack of non-invasive biomarkers that allow for the 
early identification of patients at high risk of developing 
epilepsy.
Relationship between Central Nervous System 
(CNS) Disorders and Inflammation
In recent years,  it has been suggested that neuroin-
flammatory processes play an important role in CNS 
disorders.  Thus,  the selective targeting of CNS inflam-
mation might be a viable strategy for interfering with 
the progression of neurodegenerative disorders [4].  
Translational and clinical evidence support the possibil-
ity that neuroinflammatory mediators are implicated in 
seizures and epileptogenesis [5 , 6],  putting forth the 
hypothesis that inflammation in the brain contributes to 
the generation of seizures as well as to cell damage and 
death.  In turn,  these inflammatory processes trigger 
further seizures via the activation of inflammatory 
pathways [7].  Thus,  inflammation can have a causative 
role as well as a consequential one in regards to epilep-
togenesis [7].
High-mobility group box 1 (HMGB1) protein is a 
non-histone,  DNA-binding nuclear protein belonging 
to the family of damage-associated molecular patterns 
(DAMPs) [8].  Under normal conditions,  HMGB1 
plays important roles in the regulation of gene expres-
sion and DNA repair,  and contributes to the architec-
ture of chromatin DNA [9].  Mice and rats share 100% 
of the amino-acid sequence for HMGB1,  while rodents 
and humans have a 99% homology for the protein [10].  
HMGB1 has two domains for DNA binding,  known as 
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box A and box B,  as well as a C-terminus acidic tail 
comprised of repeating glutamate and aspartic acid res-
idues [11 ,12].  A member of the DAMP family,  HMGB1 
is able to influence synaptic function in brain regions 
such as the hippocampus,  which is itself involved in 
hyperexcitability and cognitive decline during epilepto-
genesis [2].
HMGB1 has received increasing attention in regard 
to its role in epilepsy [13].  Its involvement with epilep-
togenesis is hypothesised to pertain to its role in the 
induction of inflammatory processes in the peripheral 
environment,  and in the disruption of the blood-brain 
barrier (BBB) during the initiation and development of 
epileptic conditions.
The Role of HMGB1 in Neuroinflammation  
in Epileptogenesis
HMGB1 acts as a pathogenic inflammatory response 
mediator in a range of conditions.  Evidence for its role 
in many CNS disorders and insults like stroke,  trauma,  
epilepsy and even Alzheimer’s Disease has been 
reported.  HMGB1 also acts as an initiator and amplifier 
of neuroinflammation in brain injury types that are 
highly associated with epilepsy and cognitive dysfunc-
tion ascribed to neuronal excitation [14-16].  HMGB1 
can be passively released by glia and neurons upon 
inflammasome activation,  and activates the receptor for 
advanced glycation end products (RAGE) and toll-like 
receptor (TLR) 4.  Furthermore,  it is released from 
apoptotic and necrotic cells,  and actively translocated 
from the nucleus to the cytoplasm during pyroptosis 
and inflammasome activation.  HMGB1 also contrib-
utes to increased inflammatory responses in the periph-
eral environment [3 ,13 ,15-23].  Extracellularly-released 
HMGB1 can be partially oxidized via the formation of a 
disulfide bond between cysteine 23 (C23) and cysteine 
45 (C45).  This disulfide HMGB1 isoform enhances 
neuronal excitability and proinflammatory activity 
through the activation of TLR4.  Also,  HMGB1 activity 
leads to neuronal cell loss,  neuroinflammation,  epi-
lepsy and cognitive dysfunction via the activation of its 
receptors,  RAGE and TLR4 [24].  Moreover,  HMGB1 
has been shown to suppress long-term potentiation 
(LTP) and cause memory deficits in mice in a TLR4- 
and RAGE-dependent manner.  These effects are associ-
ated with increased activation of JNK and NF-κB 
[25 , 26].  The HMGB1/TLR4 axis is speculated to be a 
key initiator of neuroinflammatory factors in epilepto-
genesis,  and has consequently gained interest in the 
field.
Electrical stimuli or chemiconvulsants,  like kainic 
acid (KA) or pilocarpine,  are used to induce the acute 
stages of epilepsy in animal models.  Researchers 
observed the translocation of HMGB1 in the brain 
within 1 h of the onset of seizures,  as well as a dramatic 
increase in plasma concentrations of HMGB1 4 h after 
seizure induction with pilocarpine [19].  This implies 
that seizure activity is a trigger for HMGB1 transloca-
tion and its subsequent release.  Seizures are also associ-
ated with the up-regulation of TLR4 and RAGE expres-
sion on neurons and astrocytes [16 , 27 , 28],  as well as 
with the upregulation of several related inflammatory 
factors in the hippocampus.  According to these studies,  
the neutralisation of HMGB1 might be a novel thera-
peutic strategy for epileptogenesis.
Previous studies have shown that the neutralisation 
of HMGB1 with an anti-HMGB1 monoclonal antibody 
(mAb) can be a potential novel strategy against multiple 
sclerosis (MS),  possibly due to the resulting inhibition 
of pro-inflammatory cytokine production in the 
peripheral environment.  Further,  the mAb therapy 
reduces CNS pathological injury [29].  Anti-HMGB1 
mAb enhances the activity of HMGB1 Box A,  a protein 
fragment with antagonistic activity against HMGB1 
[13 , 15 , 19],  and reduces the frequency and severity of 
seizure events.  Zhao et al. ’s study [13] report similar 
findings in that an anti-HMGB1 mAb treatment was 
sufficient in significantly reducing the number of spon-
taneous seizures in developing animals with induced 
epileptogenesis [13].  Studies concerned with HMGB1 
intervention in established CNS animal models propose 
that the observed neuroprotective effects are due to a 
reduction in brain and blood HMGB1 levels [20].  The 
HMGB1 receptors,  TLR4 and RAGE,  play crucial roles 
in the presence of elevated extracellular HMGB1 levels 
during epileptogenesis in epileptic models [25].  
Evidence therefore indicates that the release of endoge-
nous HMGB1 following epileptogenic events is involved 
in the pathogenesis of seizures,  and likewise contributes 
to the recurrence of seizures.  HMGB1 neutralisation 
therapies have been shown to be beneficial,  and confer 
remarkable neuroprotection in several models of neu-
roinflammation,  further supporting the contention for 
its use as a novel therapy for epileptogenesis.
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The Role of HMGB1 on Blood-brain Barrier 
(BBB) Disruption in Epileptogenesis
Recent studies suggest the involvement of HMGB1 
in epileptogenesis,  especially via the disruption of the 
BBB in contributing to the pathogenesis of epilepsy 
[19].  HMGB1-related break-down of the BBB is tied to 
cognitive deficits in aged rats [30].  BBB disruption in 
the presence of HMGB1 is widely associated with many 
CNS disorders,  such as brain trauma and epilepsy.  In 
these CNS disorders,  inflammatory events occur on 
brain vessels,  leading to serum albumin extravasation,  
which marks BBB dysfunction,  thus suggesting the 
involvement of HMGB1 in the disruption of vascular 
barriers [31].  In one study,  BBB break-down was 
observed 4 h after pilocarpine treatment,  while leakage 
was significantly decreased after HMGB1 neutralisation 
with intravenous anti-HMGB1 mAbs,  as observed with 
Evans Blue,  a serum albumin marker [19].  The benefits 
of anti-HMGB1 mAb have been demonstrated in other 
animal models of epilepsy as well.
Neuroinflammation directly alters BBB permeability 
via cytokine-mediated activation of metalloproteinases,  
or via the disruption of tight junctions [32 , 33].  This 
suggests the likely benefit of anti-inflammatory treat-
ment for epileptogenesis.  In addition,  glial and astro-
cyte activation is purported to serve an important role 
in the development of epilepsy in animal models.  Since 
HMGB1 might mediate microglial activation via the 
TLR4/NF-κB signalling pathway [6],  and is also impli-
cated in the break-down of the BBB and secreted in the 
CNS and peripherally,  an anti-inflammatory therapeu-
tic strategy might prove to be beneficial in treating epi-
leptogenesis.
HMGB1: A Biomarker of Epileptogenesis
The translocation and release of HMGB1 occur in 
different kinds of epilepsy as evidenced in pharmaco-
logical studies using animal brains,  as well as in clinical 
specimens [15].  Abnormal extracellular HMGB1 levels 
contribute to the pathophysiology of epilepsy-related 
hyperexcitability,  which might in turn contribute to 
seizure onset.  Thus,  HMGB1 might play a crucial role 
in contributing to the onset of epilepsy-related hyperex-
citability [16].  HMGB1 expression was significantly 
elevated in the hippocampus and cortex 24 h after 
KA-induced status epilepticus,  and increased in plasma 
4 h after pilocarpine treatment,  suggesting the poten-
tially crucial role of HMGB1 in epilepsy [34].  Anti-
HMGB1 mAb is able to reduce the frequency of seizures 
and to improve cognitive function,  additionally sup-
porting evidence for using HMGB1 as a biomarker of 
epileptogenesis [19].
Similarly,  anti-HMGB1 mAb treatment inhibits BBB 
leakage and HMGB1 translocation in peripheral sites 
after pilocarpine induction,  suggesting that the inhibi-
tion of HMGB1 translocation potentially reduces or 
affects BBB permeability [19].  The cited studies impli-
cate HMGB1 in the generation of seizures,  thus indi-
cating a potentially important target in epileptogenesis.  
HMGB1 levels in plasma could be a reliable biomarker 
for epileptogenesis and seizure recurrence,  further 
implying that treatment using anti-HMGB1 antibodies 
might be a novel therapeutic strategy for epileptogene-
sis.
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